GlassScriptPhysician profile
Goran T Rudic
NPI 1164491940
$2,284.44
in general payments reported to CMS, 2019-2025
22 companies · $66.77 in 2025
The $66.77 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,184 · 2022: $11.71 · 2024: $21.87 · 2025: $66.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $88.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $88.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $432.05 | 2019 | |
| Pfizer INC. | $262.55 | 2019 | |
| Novo Nordisk INC | $207.16 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $175.04 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.71 | 2019 | |
| Janssen Pharmaceuticals, INC | $171.36 | 2019 | |
| Merck Sharp & Dohme LLC | $138.29 | 2019 | |
| Novartis Pharmaceuticals Corporation | $130.73 | 2019 | |
| Supernus Pharmaceuticals, INC. | $127.07 | 2019 | |
| Lilly USA, LLC | $123.11 | 2019-2022 | |
| Allergan, INC. | $63.83 | 2019 | |
| Amgen INC. | $58.92 | 2019 | |
| Glaxosmithkline, LLC. | $43.17 | 2025 | Shingrix, Flulaval Quadrivalent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.70 | 2019 | |
| Exact Sciences Corporation | $23.60 | 2025 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $21.87 | 2024 | Heplisav-B |
| Teva Pharmaceuticals USA, INC. | $21.85 | 2019 | |
| Eisai INC. | $18.93 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $17.65 | 2019 | |
| Vertical Pharmaceuticals, LLC | $17.20 | 2019 | |
| Astellas Pharma US INC | $13.36 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Goran Rudic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.